Chemomab Therapeutics Ltd. has filed a definitive proxy statement regarding its proposed merger with Scipher Medicine Corporation. This merger, which is expected to be completed in the fourth quarter of 2026, aims to consolidate operations and enhance Chemomab's market presence in the pharmaceutical preparations industry. The merger could significantly alter the competitive landscape in the sector.

Chemomab Therapeutics Ltd. is an Israeli company specializing in pharmaceutical preparations, listed on Nasdaq under the ticker CMMB. It has undergone several name changes in its history, previously known as Anchiano Therapeutics Ltd. and BioCancell Ltd. The company has been actively filing various forms with the SEC, including a recent S-4/A on October 29, 2026, and a 6-K on October 19, 2026.

The definitive proxy statement, filed on October 30, 2026, outlines the details of the merger agreement signed on July 7, 2026. According to the filing, the merger will involve Chemomab Israel, a wholly owned subsidiary of Chemomab Parent, merging with Scipher Medicine Corporation. Following the merger, Scipher will become a wholly owned subsidiary of Chemomab Parent, which is expected to enhance operational efficiencies and market reach.

The filing states, "The Merger is expected to be completed in the fourth calendar quarter of 2026 and if it is completed, then the business of Scipher will combine with the business of Chemomab Israel in Chemomab Parent." This strategic move may impact stakeholders, including shareholders of both companies, as the merger aims to create a more robust entity in the pharmaceutical space.

What's next for Chemomab Therapeutics is the anticipated completion of the merger, pending the satisfaction of closing conditions. The filing does not specify any further steps beyond this point, but the implications of this merger could resonate throughout the pharmaceutical preparations industry.